Klinisch-pharmakologische Aspekte kardioaktiver Pharmaka

  • E. Erdmann
  • R. H. G. Schwinger
  • M. Böhm
Part of the Klinische Anästhesiologie und Intensivtherapie book series (KAI, volume 47)

Zusammenfassung

In den letzten Jahren hat sich gezeigt, daß die kardialen Wirkungen kreislaufaktiver Substanzen sehr differenziert hinsichtlich bestehender Erkrankungen der Patienten, ihres Alters und einer eventuellen Begleitmedikation betrachtet werden müssen. Wirkungen und Nebenwirkungen treten von Fall zu Fall verschieden in Erscheinung. Pharmakologische Untersuchungen an gesunden jungen Tieren können neben den speziesbedingten Unterschieden meist nicht die Wirkungen erfassen, die bei Patienten z. B. mit unterschiedlichen Grundkrankheiten auftreten [2]. Sensibilisierungen und Desensibilisierungen von Rezeptoren und zellulären Enzymen sowie Toleranzentwicklungen, die zu erhöhten oder verminderten Empfindlichkeiten gegenüber Katecholaminen und anderen Medikamenten führen, spielen eine zunehmende Rolle bei unseren Entscheidungen. Therapiekonzepte haben zu berücksichtigen, daß sich Wirkungen und sogar Wirkungsmechanismen bei verschiedenen Krankheitszuständen wesentlich ändern.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. 1.
    Böhm M, Diet F, Feiler G, Kemkes B, Kreuzer E, Weinhold C, Erdmann E (1988) Subsensitivity of the failing human heart to isoprenaline and milrinone is related to 3-adrenoceptor downregulation. J Cardiovasc Pharmacol 12: 726–732PubMedCrossRefGoogle Scholar
  2. 2.
    Böhm M, Diet F, Pieske B, Erdmann E (1989) Screening of positive inotropic agents in isolated cardiac preparations from different sources. J Pharmacol Meth 699: 33–44CrossRefGoogle Scholar
  3. 3.
    Böhm M, Pieske B, Schnabel P, Schwinger RGH, Kemkes B, Klövekorn WP, Erdmann E (1989) Reduced effect of dopexamine on force of contraction in the failing human heart despite preserved 02-adrenoceptor subpopulation. J Cardiovasc Pharmacol 14: 549–559PubMedCrossRefGoogle Scholar
  4. 4.
    Böhm M, Gierschik P, Jakobs KH, Pieske B, Schnabel P, Ungerer M, Erdmann E (1990) Increase of Gia in human hearts with dilated but not ischemic cardiomyopathy. Circulation 82: 1249–65PubMedCrossRefGoogle Scholar
  5. 5.
    Böhm M, Morano I, Pieske B, Rüegg JC, Wankerl M, Zimmermann R, Erdmann E (1991) Contribution of cAMP-phosphodiesterase inhibition and sensitization of the contractile proteins for calcium to the inotropic effect of pimobendan in the failing human myocardium. Circ Res 68: 689–701PubMedGoogle Scholar
  6. 6.
    Bristow MB, Ginsburg R, Minobe W, Cubicotti RS, Sageman WS, Lurie K, Billingham ME, Harrison DC, Stinson EB (1982) Decreased catecholamine sensitivity and beta-adrenergicreceptor density in failing human hearts. N Engl J Med 307: 205–211PubMedCrossRefGoogle Scholar
  7. 7.
    Brodde OE, (1991) f31- and 132-adrenoceptors in the human heart. Properties, function and alterations in chronic heart failure. Pharmacol Rev 43:203–242PubMedGoogle Scholar
  8. 8.
    Cohn JN, Levine TB, Olivari MT, Garberg V, Lura D, Francis GS, Simson AB, Rector T (1984) Plasma noradrenaline as a guide to prognosis in patients with chronic congestive heart failure. N Engl J Med 311: 819–823PubMedCrossRefGoogle Scholar
  9. 9.
    DiBianco R, Shabetai R, Kostuk Wet al. (1989) A comparison of oral milrinone, digoxin, and their combination in the treatment of patients with chronic heart failure. N Engl J Med 320: 677–683CrossRefGoogle Scholar
  10. 10.
    Dies F, Krell MJ, Whitlow P, Liang CH, Goldenberg I, Applefeld MM, Gilbert EM (1986) Intermitttent dobutamine in ambulatory outpatients with chronic cardiac failure. Circulation 74 (Suppl II): II - 138Google Scholar
  11. 11.
    Feldmann AM, Cates AE, Veazey WB, Hershberger RE, Bristow MR, Baughman KL, Baumgartner WA, van Dop C (1988) Increase of the 40,000-mol wt pertussis toxin substrate ( G protein) in the failing human heart. J Clin Invest 82: 189–197Google Scholar
  12. 12.
    Kubo SH, Gollub S, Bourge R et al. (1992) Beneficial effects of pimobedan on exercise tolerance and quality of life in patients with heart failure. Circulation 85: 942–949PubMedGoogle Scholar
  13. 13.
    Massie BM, Berk MR, Brozena S, Elkayam U, Plehn J, Kukin M, Murphy B, Neuberg G, Steingart R, DeHaan H (1992) Can further benefit be achieved by adding a vasodilatator to triple therapy in CHF; results of the flosequinan-ACE inhibitor trial (FACET)? AHA I-645 (Abstr)Google Scholar
  14. 14.
    Neumann J, Schmitz W, von Meyerinck L, Scholz HJ, Döring V, Kalmar P (1988) Increase in myocardial Gi-proteins in heart failure. Lancet II: 936–937CrossRefGoogle Scholar
  15. 15.
    Packer M, Carver JR, Rodeheffer RJ et al. (1991) Effect of oral milrinone on mortality in severe chronic heart failure. N Engl J Med 325: 1468–1475PubMedCrossRefGoogle Scholar
  16. 16.
    Packer M, Pitt B (1992) Efficacy of flosequinan in patients with heart failure who are withdrawn from therapy with converting-enzyme inhibitors: a doubleblind controlled study. Circulation 86 (Suppl I): I - 644Google Scholar
  17. 17.
    Schwinger RHG, Böhm M, Erdmann E (1990) Evidence against spare or uncoupled 13-adrenoceptors in the human heart. Am Heart J 119: 899–904PubMedCrossRefGoogle Scholar
  18. 18.
    Schwinger RGH, Böhm M, Erdmann E (1990) Effectiveness of cardiac glycosides in human myocardium with and without „downregulated“ 3-adrenoceptors. J Cardiovasc Pharmacol 15: 692–697PubMedCrossRefGoogle Scholar
  19. 19.
    Schwinger RHG, Böhm M, La Rosée K, Schmidt U, Schulz C, Erdmann E (1992) Na-channel activations increase cardiac glykoside sensitivity in failing human myocardium. J Cardiovasc Pharmacol 19: 554–561PubMedCrossRefGoogle Scholar
  20. 20.
    Schwinger RHG, Böhm M, Uhlmann R, Erdmann E (1992) BDF9148 and Quabain are effective to restore the normal force-frequency relationship in failing human myocardium. Circulation 86 (Suppl I): I - 284Google Scholar
  21. 21.
    Ungerer M, Böhm M, Elce JS, Erdmann M, Lohse MJ (1993) Altered expression of 3-adrenergic receptor kinase and 01-adrenergic receptors in the failing human heart. Circulation 87: 454–463PubMedGoogle Scholar
  22. 22.
    Uretsky BF, Jessup M, Konstam A et al. (1990) Multicenter trial of oral enoximone in patients with moderate to moderately severe congestive heart failure. Circulation 82: 774–780PubMedCrossRefGoogle Scholar
  23. 23.
    Waagstein F, Caidahl K, Wallentin I, Bergh CH, Hjalmarson A (1989) Long-term 3-blockade in dilated cardiomyopathy. Circulation 80: 551PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1995

Authors and Affiliations

  • E. Erdmann
  • R. H. G. Schwinger
  • M. Böhm

There are no affiliations available

Personalised recommendations